Literature DB >> 23596117

Bone marrow findings in HIV-positive patients with Kaposi sarcoma herpesvirus-associated multicentric Castleman disease.

Girish Venkataraman1, Thomas S Uldrick, Karen Aleman, Deirdre O'Mahony, Donald S Karcher, Seth M Steinberg, Mark A Raffeld, Vickie Marshall, Denise Whitby, Richard F Little, Robert Yarchoan, Stefania Pittaluga, Irina Maric.   

Abstract

Kaposi sarcoma herpesvirus (KSHV), also known as human herpesvirus-8, is associated with 1 form of multicentric Castleman disease (MCD) and is the etiologic agent for most MCD in human immunodeficiency virus (HIV)-infected patients. Diagnosis is usually determined by lymph node biopsy. Bone marrow findings in KSHV-MCD are not well characterized. We conducted histomorphologic and immunohistochemical evaluation of bone marrow biopsy specimens in HIV-infected patients with KSHV-MCD, including evaluation for KSHV latency-associated nuclear antigen. Findings were correlated with clinical features and KSHV viral load. Reactive plasmacytosis was the predominant feature. Lymphoid aggregates were less common and not diagnostic of KSHV-MCD. Forty-eight percent of cases contained scattered KSHV-infected mononuclear cells. Although patients were generally cytopenic, bone marrow biopsy specimens were normocellular to hypercellular except in patients receiving hematotoxic therapy. Bone marrow biopsy specimens in KSHV-MCD patients recapitulate findings of interleukin-6 excess. In patients with HIV, unexplained cytopenias, and bone marrow plasmacytosis, evaluation for KSHV-MCD is warranted.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23596117      PMCID: PMC6999850          DOI: 10.1309/AJCPKGF7U8AWQBVG

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  34 in total

1.  Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6.

Authors:  Y Aoki; E S Jaffe; Y Chang; K Jones; J Teruya-Feldstein; P S Moore; G Tosato
Journal:  Blood       Date:  1999-06-15       Impact factor: 22.113

2.  Serum viral interleukin-6 in AIDS-related multicentric Castleman disease.

Authors:  Y Aoki; G Tosato; T W Fonville; S Pittaluga
Journal:  Blood       Date:  2001-04-15       Impact factor: 22.113

3.  A quantification of human cells using an ERV-3 real time PCR assay.

Authors:  C C Yuan; W Miley; D Waters
Journal:  J Virol Methods       Date:  2001-02       Impact factor: 2.014

4.  Detection and characterization of human herpesvirus-8-infected cells in bone marrow biopsies of human immunodeficiency virus-positive patients.

Authors:  F Meggetto; E Cesarman; L Mourey; P Massip; G Delsol; P Brousset
Journal:  Hum Pathol       Date:  2001-03       Impact factor: 3.466

5.  Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice.

Authors:  S J Brandt; D M Bodine; C E Dunbar; A W Nienhuis
Journal:  J Clin Invest       Date:  1990-08       Impact factor: 14.808

6.  Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group.

Authors:  S Schreiber; R N Fedorak; O H Nielsen; G Wild; C N Williams; S Nikolaus; M Jacyna; B A Lashner; A Gangl; P Rutgeerts; K Isaacs; S J van Deventer; J C Koningsberger; M Cohard; A LeBeaut; S B Hanauer
Journal:  Gastroenterology       Date:  2000-12       Impact factor: 22.682

7.  The bone marrow in human immunodeficiency virus (HIV)-related disease. Morphology and clinical correlation.

Authors:  D S Karcher; A R Frost
Journal:  Am J Clin Pathol       Date:  1991-01       Impact factor: 2.493

8.  Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas.

Authors:  E Cesarman; Y Chang; P S Moore; J W Said; D M Knowles
Journal:  N Engl J Med       Date:  1995-05-04       Impact factor: 91.245

9.  Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes.

Authors:  F Rousset; E Garcia; T Defrance; C Péronne; N Vezzio; D H Hsu; R Kastelein; K W Moore; J Banchereau
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205

10.  Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial.

Authors:  Laurence Gérard; Alice Bérezné; Lionel Galicier; Véronique Meignin; Martine Obadia; Nathalie De Castro; Christine Jacomet; Renaud Verdon; Isabelle Madelaine-Chambrin; Emmanuelle Boulanger; Sylvie Chevret; Felix Agbalika; Eric Oksenhendler
Journal:  J Clin Oncol       Date:  2007-08-01       Impact factor: 44.544

View more
  14 in total

1.  International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease.

Authors:  David C Fajgenbaum; Thomas S Uldrick; Adam Bagg; Dale Frank; David Wu; Gordan Srkalovic; David Simpson; Amy Y Liu; David Menke; Shanmuganathan Chandrakasan; Mary Jo Lechowicz; Raymond S M Wong; Sheila Pierson; Michele Paessler; Jean-François Rossi; Makoto Ide; Jason Ruth; Michael Croglio; Alexander Suarez; Vera Krymskaya; Amy Chadburn; Gisele Colleoni; Sunita Nasta; Raj Jayanthan; Christopher S Nabel; Corey Casper; Angela Dispenzieri; Alexander Fosså; Dermot Kelleher; Razelle Kurzrock; Peter Voorhees; Ahmet Dogan; Kazuyuki Yoshizaki; Frits van Rhee; Eric Oksenhendler; Elaine S Jaffe; Kojo S J Elenitoba-Johnson; Megan S Lim
Journal:  Blood       Date:  2017-01-13       Impact factor: 22.113

2.  18F-fluorodeoxyglucose Positron Emission Tomography in Kaposi Sarcoma Herpesvirus-Associated Multicentric Castleman Disease: Correlation With Activity, Severity, Inflammatory and Virologic Parameters.

Authors:  Mark N Polizzotto; Corina Millo; Thomas S Uldrick; Karen Aleman; Millie Whatley; Kathleen M Wyvill; Deirdre O'Mahony; Vickie Marshall; Denise Whitby; Roberto Maass-Moreno; Seth M Steinberg; Richard F Little; Robert Yarchoan
Journal:  J Infect Dis       Date:  2015-03-31       Impact factor: 5.226

3.  GATA2 deficiency-associated bone marrow disorder differs from idiopathic aplastic anemia.

Authors:  Karthik A Ganapathi; Danielle M Townsley; Amy P Hsu; Diane C Arthur; Christa S Zerbe; Jennifer Cuellar-Rodriguez; Dennis D Hickstein; Sergio D Rosenzweig; Raul C Braylan; Neal S Young; Steven M Holland; Katherine R Calvo
Journal:  Blood       Date:  2014-10-30       Impact factor: 22.113

4.  Clinical Features and Outcomes of Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV)-associated Inflammation: Prospective Characterization of KSHV Inflammatory Cytokine Syndrome (KICS).

Authors:  Mark N Polizzotto; Thomas S Uldrick; Kathleen M Wyvill; Karen Aleman; Vickie Marshall; Victoria Wang; Denise Whitby; Stefania Pittaluga; Elaine S Jaffe; Corina Millo; Giovanna Tosato; Richard F Little; Seth M Steinberg; Irini Sereti; Robert Yarchoan
Journal:  Clin Infect Dis       Date:  2015-12-12       Impact factor: 9.079

Review 5.  Treatment of Kaposi Sarcoma Herpesvirus-Associated Multicentric Castleman Disease.

Authors:  Kathryn Lurain; Robert Yarchoan; Thomas S Uldrick
Journal:  Hematol Oncol Clin North Am       Date:  2018-02       Impact factor: 3.722

6.  Laparoscopic treatment for retroperitoneal hyaline-vascular type localized Castleman's disease (LCD) in the iliac vessel region.

Authors:  Aiwen Le; Lili Shan; Zhonghai Wang; Xiaoyun Dai; Tianhui Xiao; Rong Zhuo; Rui Yuan
Journal:  Int J Clin Exp Med       Date:  2015-11-15

7.  Multicentric Castleman's Disease and Kaposi's Sarcoma in a HIV-Positive Patient on Highly Active Antiretroviral Therapy.

Authors:  Lauro Ortega; Chad J Cooper; Salman Otoukesh; Mona Mojtahedzadeh; Claudia S Didia; Alireza Torabi; Zeina Nahleh
Journal:  Rare Tumors       Date:  2014-08-06

8.  Clinical Factors Associated with Long-Term Complete Remission versus Poor Response to Chemotherapy in HIV-Infected Children and Adolescents with Kaposi Sarcoma Receiving Bleomycin and Vincristine: A Retrospective Observational Study.

Authors:  Nader Kim El-Mallawany; William Kamiyango; Jeremy S Slone; Jimmy Villiera; Carrie L Kovarik; Carrie M Cox; Dirk P Dittmer; Saeed Ahmed; Gordon E Schutze; Michael E Scheurer; Peter N Kazembe; Parth S Mehta
Journal:  PLoS One       Date:  2016-04-15       Impact factor: 3.240

9.  Human Mesenchymal Stem Cells of Diverse Origins Support Persistent Infection with Kaposi's Sarcoma-Associated Herpesvirus and Manifest Distinct Angiogenic, Invasive, and Transforming Phenotypes.

Authors:  Myung-Shin Lee; Hongfeng Yuan; Hyungtaek Jeon; Ying Zhu; Seungmin Yoo; Songtao Shi; Brian Krueger; Rolf Renne; Chun Lu; Jae U Jung; Shou-Jiang Gao
Journal:  mBio       Date:  2016-01-26       Impact factor: 7.867

10.  A challenging case of rapid progressive Kaposi sarcoma after renal transplantation: diagnostics by FDG PET/CT.

Authors:  Stefan Reuter; Alexis Vrachimis; Sebastian Huss; Eva Wardelmann; Mathias Weckesser; Hermann Pavenstädt
Journal:  Medicine (Baltimore)       Date:  2014-09       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.